Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes
Anticipated Profits From Biosimilar Candidates To Expand Future Development
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
You may also be interested in...
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.
Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.